1. Home
  2. EOD vs LRMR Comparison

EOD vs LRMR Comparison

Compare EOD & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

N/A

Current Price

$5.73

Market Cap

272.6M

Sector

Finance

ML Signal

N/A

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$3.15

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EOD
LRMR
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.6M
253.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EOD
LRMR
Price
$5.73
$3.15
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $14.20
AVG Volume (30 Days)
113.7K
★ 1.3M
Earning Date
01-01-0001
11-16-2026
Dividend Yield
★ 9.28%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$1.92
52 Week High
$6.74
$6.42

Technical Indicators

Market Signals
Indicator
EOD
LRMR
Relative Strength Index (RSI) 27.73 58.96
Support Level $5.51 $2.89
Resistance Level $6.55 $4.25
Average True Range (ATR) 0.13 0.30
MACD -0.04 0.09
Stochastic Oscillator 10.14 66.40

Price Performance

Historical Comparison
EOD
LRMR

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Share on Social Networks: